Preeclampsia resident survival guide: Difference between revisions
Agnesrinky (talk | contribs) |
Agnesrinky (talk | contribs) |
||
Line 9: | Line 9: | ||
==Causes== | ==Causes== | ||
The high risk factors of [[preeclampsia]] are | The high risk factors of [[preeclampsia]] are | ||
* History of any [[hypertensive disease]] during a previous [[pregnancy]]. | |||
* [[Maternal]] disease such as[[chronic kidney disease]], [[autoimmune diseases]], [[diabetes]], [[chronic hypertension]]. | *History of any [[hypertensive disease]] during a previous [[pregnancy]]. | ||
*[[Maternal]] disease such as[[chronic kidney disease]], [[autoimmune diseases]], [[diabetes]], [[chronic hypertension]]. | |||
Women are at moderate risk if they are | Women are at moderate risk if they are | ||
* [[Nulliparous]] | |||
* ≥40 years of age | *[[Nulliparous]] | ||
* [[Body mass index]] (BMI) ≥ 35 kg/m <ref name="pmid29899139">{{cite journal |vauthors=Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S, Hall DR, Warren CE, Adoyi G, Ishaku S |title=Hypertensive Disorders of Pregnancy: ISSHP Classification, Diagnosis, and Management Recommendations for International Practice |journal=Hypertension |volume=72 |issue=1 |pages=24–43 |date=July 2018 |pmid=29899139 |doi=10.1161/HYPERTENSIONAHA.117.10803 |url= |issn=}}</ref> | *≥40 years of age | ||
* Family history of [[preeclampsia]] | *[[Body mass index]] (BMI) ≥ 35 kg/m <ref name="pmid29899139">{{cite journal |vauthors=Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S, Hall DR, Warren CE, Adoyi G, Ishaku S |title=Hypertensive Disorders of Pregnancy: ISSHP Classification, Diagnosis, and Management Recommendations for International Practice |journal=Hypertension |volume=72 |issue=1 |pages=24–43 |date=July 2018 |pmid=29899139 |doi=10.1161/HYPERTENSIONAHA.117.10803 |url= |issn=}}</ref> | ||
* Multifetal [[pregnancy]] | *Family history of [[preeclampsia]] | ||
* A [[pregnancy]] interval of more than 10 years<ref name="urlOverview | Hypertension in pregnancy: diagnosis and management | Guidance | NICE">{{cite web |url=https://www.nice.org.uk/guidance/ng133 |title=Overview | Hypertension in pregnancy: diagnosis and management | Guidance | NICE |author= |authorlink= |coauthors= |date= |format= |work= |publisher= |pages= |language= |archiveurl= |archivedate= |quote= |accessdate=}}</ref> | *Multifetal [[pregnancy]] | ||
*A [[pregnancy]] interval of more than 10 years<ref name="urlOverview | Hypertension in pregnancy: diagnosis and management | Guidance | NICE">{{cite web |url=https://www.nice.org.uk/guidance/ng133 |title=Overview | Hypertension in pregnancy: diagnosis and management | Guidance | NICE |author= |authorlink= |coauthors= |date= |format= |work= |publisher= |pages= |language= |archiveurl= |archivedate= |quote= |accessdate=}}</ref> | |||
Additional clinical factors: | Additional clinical factors: | ||
* Raised mean arterial blood pressure before 15 weeks’ gestation<ref name="pmid21474517">{{cite journal |vauthors=North RA, McCowan LM, Dekker GA, Poston L, Chan EH, Stewart AW, Black MA, Taylor RS, Walker JJ, Baker PN, Kenny LC |title=Clinical risk prediction for pre-eclampsia in nulliparous women: development of model in international prospective cohort |journal=BMJ |volume=342 |issue= |pages=d1875 |date=April 2011 |pmid=21474517 |pmc=3072235 |doi=10.1136/bmj.d1875 |url= |issn=}}</ref> | |||
* Polycystic ovarian syndrome<ref name="pmid30674081">{{cite journal |vauthors=Bahri Khomami M, Joham AE, Boyle JA, Piltonen T, Silagy M, Arora C, Misso ML, Teede HJ, Moran LJ |title=Increased maternal pregnancy complications in polycystic ovary syndrome appear to be independent of obesity-A systematic review, meta-analysis, and meta-regression |journal=Obes Rev |volume=20 |issue=5 |pages=659–674 |date=May 2019 |pmid=30674081 |doi=10.1111/obr.12829 |url= |issn=}}</ref><ref name="pmid23800002">{{cite journal |vauthors=Qin JZ, Pang LH, Li MJ, Fan XJ, Huang RD, Chen HY |title=Obstetric complications in women with polycystic ovary syndrome: a systematic review and meta-analysis |journal=Reprod Biol Endocrinol |volume=11 |issue= |pages=56 |date=June 2013 |pmid=23800002 |pmc=3737012 |doi=10.1186/1477-7827-11-56 |url= |issn=}}</ref> | *Raised mean arterial blood pressure before 15 weeks’ gestation<ref name="pmid21474517">{{cite journal |vauthors=North RA, McCowan LM, Dekker GA, Poston L, Chan EH, Stewart AW, Black MA, Taylor RS, Walker JJ, Baker PN, Kenny LC |title=Clinical risk prediction for pre-eclampsia in nulliparous women: development of model in international prospective cohort |journal=BMJ |volume=342 |issue= |pages=d1875 |date=April 2011 |pmid=21474517 |pmc=3072235 |doi=10.1136/bmj.d1875 |url= |issn=}}</ref> | ||
* Sleep disordered breathing <ref name="pmid23911687">{{cite journal |vauthors=Pamidi S, Pinto LM, Marc I, Benedetti A, Schwartzman K, Kimoff RJ |title=Maternal sleep-disordered breathing and adverse pregnancy outcomes: a systematic review and metaanalysis |journal=Am J Obstet Gynecol |volume=210 |issue=1 |pages=52.e1–52.e14 |date=January 2014 |pmid=23911687 |doi=10.1016/j.ajog.2013.07.033 |url= |issn=}}</ref> | *Polycystic ovarian syndrome<ref name="pmid30674081">{{cite journal |vauthors=Bahri Khomami M, Joham AE, Boyle JA, Piltonen T, Silagy M, Arora C, Misso ML, Teede HJ, Moran LJ |title=Increased maternal pregnancy complications in polycystic ovary syndrome appear to be independent of obesity-A systematic review, meta-analysis, and meta-regression |journal=Obes Rev |volume=20 |issue=5 |pages=659–674 |date=May 2019 |pmid=30674081 |doi=10.1111/obr.12829 |url= |issn=}}</ref><ref name="pmid23800002">{{cite journal |vauthors=Qin JZ, Pang LH, Li MJ, Fan XJ, Huang RD, Chen HY |title=Obstetric complications in women with polycystic ovary syndrome: a systematic review and meta-analysis |journal=Reprod Biol Endocrinol |volume=11 |issue= |pages=56 |date=June 2013 |pmid=23800002 |pmc=3737012 |doi=10.1186/1477-7827-11-56 |url= |issn=}}</ref> | ||
* Various infections such as periodontal disease, urinary tract infections<ref name="pmid17577649">{{cite journal |vauthors=Rustveld LO, Kelsey SF, Sharma R |title=Association between maternal infections and preeclampsia: a systematic review of epidemiologic studies |journal=Matern Child Health J |volume=12 |issue=2 |pages=223–42 |date=March 2008 |pmid=17577649 |doi=10.1007/s10995-007-0224-1 |url= |issn=}}</ref> and helicobacter pylori<ref name="pmid29388723">{{cite journal |vauthors=Bellos I, Daskalakis G, Pergialiotis V |title=Helicobacter pylori infection increases the risk of developing preeclampsia: A meta-analysis of observational studies |journal=Int J Clin Pract |volume=72 |issue=2 |pages= |date=February 2018 |pmid=29388723 |doi=10.1111/ijcp.13064 |url= |issn=}}</ref>. | *Sleep disordered breathing <ref name="pmid23911687">{{cite journal |vauthors=Pamidi S, Pinto LM, Marc I, Benedetti A, Schwartzman K, Kimoff RJ |title=Maternal sleep-disordered breathing and adverse pregnancy outcomes: a systematic review and metaanalysis |journal=Am J Obstet Gynecol |volume=210 |issue=1 |pages=52.e1–52.e14 |date=January 2014 |pmid=23911687 |doi=10.1016/j.ajog.2013.07.033 |url= |issn=}}</ref> | ||
* Vaginal bleeding for at least five days during pregnancy increases preeclampsia risk<ref name="pmid21474517">{{cite journal |vauthors=North RA, McCowan LM, Dekker GA, Poston L, Chan EH, Stewart AW, Black MA, Taylor RS, Walker JJ, Baker PN, Kenny LC |title=Clinical risk prediction for pre-eclampsia in nulliparous women: development of model in international prospective cohort |journal=BMJ |volume=342 |issue= |pages=d1875 |date=April 2011 |pmid=21474517 |pmc=3072235 |doi=10.1136/bmj.d1875 |url= |issn=}}</ref> | *Various infections such as periodontal disease, urinary tract infections<ref name="pmid17577649">{{cite journal |vauthors=Rustveld LO, Kelsey SF, Sharma R |title=Association between maternal infections and preeclampsia: a systematic review of epidemiologic studies |journal=Matern Child Health J |volume=12 |issue=2 |pages=223–42 |date=March 2008 |pmid=17577649 |doi=10.1007/s10995-007-0224-1 |url= |issn=}}</ref> and helicobacter pylori<ref name="pmid29388723">{{cite journal |vauthors=Bellos I, Daskalakis G, Pergialiotis V |title=Helicobacter pylori infection increases the risk of developing preeclampsia: A meta-analysis of observational studies |journal=Int J Clin Pract |volume=72 |issue=2 |pages= |date=February 2018 |pmid=29388723 |doi=10.1111/ijcp.13064 |url= |issn=}}</ref>. | ||
* Use of oocyte donation has a higher risk of preeclampsia than in vitro fertilization (IVF) without oocyte donation or natural conception.<ref name="pmid27007875">{{cite journal |vauthors=Blázquez A, García D, Rodríguez A, Vassena R, Figueras F, Vernaeve V |title=Is oocyte donation a risk factor for preeclampsia? A systematic review and meta-analysis |journal=J Assist Reprod Genet |volume=33 |issue=7 |pages=855–63 |date=July 2016 |pmid=27007875 |pmc=4930777 |doi=10.1007/s10815-016-0701-9 |url= |issn=}}</ref><ref name="pmid26627731">{{cite journal |vauthors=Masoudian P, Nasr A, de Nanassy J, Fung-Kee-Fung K, Bainbridge SA, El Demellawy D |title=Oocyte donation pregnancies and the risk of preeclampsia or gestational hypertension: a systematic review and metaanalysis |journal=Am J Obstet Gynecol |volume=214 |issue=3 |pages=328–39 |date=March 2016 |pmid=26627731 |doi=10.1016/j.ajog.2015.11.020 |url= |issn=}}</ref> | *Vaginal bleeding for at least five days during pregnancy increases preeclampsia risk<ref name="pmid21474517">{{cite journal |vauthors=North RA, McCowan LM, Dekker GA, Poston L, Chan EH, Stewart AW, Black MA, Taylor RS, Walker JJ, Baker PN, Kenny LC |title=Clinical risk prediction for pre-eclampsia in nulliparous women: development of model in international prospective cohort |journal=BMJ |volume=342 |issue= |pages=d1875 |date=April 2011 |pmid=21474517 |pmc=3072235 |doi=10.1136/bmj.d1875 |url= |issn=}}</ref> | ||
*Use of oocyte donation has a higher risk of preeclampsia than in vitro fertilization (IVF) without oocyte donation or natural conception.<ref name="pmid27007875">{{cite journal |vauthors=Blázquez A, García D, Rodríguez A, Vassena R, Figueras F, Vernaeve V |title=Is oocyte donation a risk factor for preeclampsia? A systematic review and meta-analysis |journal=J Assist Reprod Genet |volume=33 |issue=7 |pages=855–63 |date=July 2016 |pmid=27007875 |pmc=4930777 |doi=10.1007/s10815-016-0701-9 |url= |issn=}}</ref><ref name="pmid26627731">{{cite journal |vauthors=Masoudian P, Nasr A, de Nanassy J, Fung-Kee-Fung K, Bainbridge SA, El Demellawy D |title=Oocyte donation pregnancies and the risk of preeclampsia or gestational hypertension: a systematic review and metaanalysis |journal=Am J Obstet Gynecol |volume=214 |issue=3 |pages=328–39 |date=March 2016 |pmid=26627731 |doi=10.1016/j.ajog.2015.11.020 |url= |issn=}}</ref> | |||
=====Common Causes===== | =====Common Causes===== | ||
Common cause of [[preeclampsia]] include [[uteroplacental]] [[ischemia]] and [[genetic predisposition]] due to the following:<ref name="LyeBloise2013">{{cite journal|last1=Lye|first1=P.|last2=Bloise|first2=E.|last3=Dunk|first3=C.|last4=Javam|first4=M.|last5=Gibb|first5=W.|last6=Lye|first6=S.J.|last7=Matthews|first7=S.G.|title=Effect of oxygen on multidrug resistance in the first trimester human placenta|journal=Placenta|volume=34|issue=9|year=2013|pages=817–823|issn=01434004|doi=10.1016/j.placenta.2013.05.010}}</ref><ref name="MayrinkCosta2018">{{cite journal|last1=Mayrink|first1=J.|last2=Costa|first2=M. L.|last3=Cecatti|first3=J. G.|title=Preeclampsia in 2018: Revisiting Concepts, Physiopathology, and Prediction|journal=The Scientific World Journal|volume=2018|year=2018|pages=1–9|issn=2356-6140|doi=10.1155/2018/6268276}}</ref> | Common cause of [[preeclampsia]] include [[uteroplacental]] [[ischemia]] and [[genetic predisposition]] due to the following:<ref name="LyeBloise2013">{{cite journal|last1=Lye|first1=P.|last2=Bloise|first2=E.|last3=Dunk|first3=C.|last4=Javam|first4=M.|last5=Gibb|first5=W.|last6=Lye|first6=S.J.|last7=Matthews|first7=S.G.|title=Effect of oxygen on multidrug resistance in the first trimester human placenta|journal=Placenta|volume=34|issue=9|year=2013|pages=817–823|issn=01434004|doi=10.1016/j.placenta.2013.05.010}}</ref><ref name="MayrinkCosta2018">{{cite journal|last1=Mayrink|first1=J.|last2=Costa|first2=M. L.|last3=Cecatti|first3=J. G.|title=Preeclampsia in 2018: Revisiting Concepts, Physiopathology, and Prediction|journal=The Scientific World Journal|volume=2018|year=2018|pages=1–9|issn=2356-6140|doi=10.1155/2018/6268276}}</ref> | ||
* The formation of [[atheromatous plaques]] and [[fibrinoid necrosis]] of the [[spiral]] [[vessel walls]] | *The formation of [[atheromatous plaques]] and [[fibrinoid necrosis]] of the [[spiral]] [[vessel walls]] | ||
* [[Oxidative stress]] in [[trophoblast cells]] | *[[Oxidative stress]] in [[trophoblast cells]] | ||
* [[Apoptosis]] in [[trophoblast cells]] | *[[Apoptosis]] in [[trophoblast cells]] | ||
* [[Systemic inflammatory response]] | *[[Systemic inflammatory response]] | ||
* [[Vasospasm]] | *[[Vasospasm]] | ||
* [[Platelet]] aggregation | *[[Platelet]] aggregation | ||
* [[Thrombin]] formation | *[[Thrombin]] formation | ||
* Deposition of the [[fibrin]] in multiple [[organs]] | *Deposition of the [[fibrin]] in multiple [[organs]] | ||
==Diagnosis== | ==Diagnosis== | ||
Line 164: | Line 169: | ||
{| class="wikitable" | {| class="wikitable" | ||
|- | |- | ||
! | ! align="center" style="background: #4479BA; color: #FFFFFF " |Drugs for urgent controlling of [[hypertension]] in [[preeclampsia]]<ref>{{cite journal|title=Gestational Hypertension and Preeclampsia|journal=Obstetrics & Gynecology|volume=135|issue=6|year=2020|pages=e237–e260|issn=0029-7844|doi=10.1097/AOG.0000000000003891}}</ref> | ||
! | ! align="center" style="background: #4479BA; color: #FFFFFF " |Dose!! align="center" style="background: #4479BA; color: #FFFFFF " |Specific considration!! align="center" style="background: #4479BA; color: #FFFFFF " |Onset of action | ||
|- | |- | ||
| [[Labetalol]]|| 10–20 mg IV | |[[Labetalol]]||10–20 mg IV<nowiki><br></nowiki> | ||
then 20–80 mg every 10–30 minutes upto a maximum dosage of 300 mg;<nowiki><br></nowiki> | |||
or <nowiki><br></nowiki> | |||
infusion 1–2 mg/min IV | |||
|Contraindications: | |||
*[[Asthma]] | *[[Asthma]] | ||
* [[Decompensated heart failure]], | *[[Decompensated heart failure]], | ||
* [[ Heart block]] | *[[ Heart block]] | ||
* [[Bradycardia]] | *[[Bradycardia]] | ||
|| 1-2 minutes | ||1-2 minutes | ||
|- | |- | ||
| [[Hydralazine]] || 5 mg IV or IM, then 5–10 mg IV every 20–40 minutes upto a maximum dosage of 200 mg or keeping infusion of 0.5–10 mg/hr || Side effects in higher dosage: | |[[Hydralazine]]||5 mg IV or IM, then 5–10 mg IV every 20–40 minutes upto a maximum dosage of 200 mg or keeping infusion of 0.5–10 mg/hr||Side effects in higher dosage: | ||
* maternal [[hypotension]] | |||
* [[Headaches]] | *maternal [[hypotension]] | ||
*[[Headaches]] | |||
*Abnormal [[fetal heart rate]] tracings | *Abnormal [[fetal heart rate]] tracings | ||
|| 10-20 minutes | ||10-20 minutes | ||
|- | |- | ||
| [[Nifedipine]] ||10–20 mg orally, repeat in 20 minutes if needed; then 10–20 mg every 2–6 hours, maximum daily dose is 180 mg|| Side effect: | |[[Nifedipine]]||10–20 mg orally, repeat in 20 minutes if needed; then 10–20 mg every 2–6 hours, maximum daily dose is 180 mg||Side effect: | ||
* Reflex [[tachycardia]] | |||
* [[Headache]] | *Reflex [[tachycardia]] | ||
|| 5-10 minutes | *[[Headache]] | ||
||5-10 minutes | |||
|- | |- | ||
|} | |} | ||
==Do's== | ==Do's== | ||
* Patient should start low-dose aspirin if she has two or more of the moderate-risk factors | |||
*Patient should start low-dose aspirin if she has two or more of the moderate-risk factors | |||
==Don'ts== | ==Don'ts== | ||
* The content in this section is in bullet points. | |||
*The content in this section is in bullet points. | |||
==References== | ==References== |
Revision as of 10:25, 8 February 2021
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rinky Agnes Botleroo, M.B.B.S.
Synonyms and keywords:
Overview
This section provides a short and straight to the point overview of the disease or symptom. The first sentence of the overview must contain the name of the disease.
Causes
The high risk factors of preeclampsia are
- History of any hypertensive disease during a previous pregnancy.
- Maternal disease such aschronic kidney disease, autoimmune diseases, diabetes, chronic hypertension.
Women are at moderate risk if they are
- Nulliparous
- ≥40 years of age
- Body mass index (BMI) ≥ 35 kg/m [1]
- Family history of preeclampsia
- Multifetal pregnancy
- A pregnancy interval of more than 10 years[2]
Additional clinical factors:
- Raised mean arterial blood pressure before 15 weeks’ gestation[3]
- Polycystic ovarian syndrome[4][5]
- Sleep disordered breathing [6]
- Various infections such as periodontal disease, urinary tract infections[7] and helicobacter pylori[8].
- Vaginal bleeding for at least five days during pregnancy increases preeclampsia risk[3]
- Use of oocyte donation has a higher risk of preeclampsia than in vitro fertilization (IVF) without oocyte donation or natural conception.[9][10]
Common Causes
Common cause of preeclampsia include uteroplacental ischemia and genetic predisposition due to the following:[11][12]
- The formation of atheromatous plaques and fibrinoid necrosis of the spiral vessel walls
- Oxidative stress in trophoblast cells
- Apoptosis in trophoblast cells
- Systemic inflammatory response
- Vasospasm
- Platelet aggregation
- Thrombin formation
- Deposition of the fibrin in multiple organs
Diagnosis
Shown below is an algorithm summarizing the diagnosis of Pre-eclampsia.
Pregnant woman comes with Hypertension | |||||||||||||||||||||||||||||||||||||||||||||||
Take complete history | |||||||||||||||||||||||||||||||||||||||||||||||
Ask about previous obstetric history if she was previous pregnant : ❑ Ask about previous pregnancies including miscarriages and terminations. ❑ Length of gestation. ❑ Ask about mode of delivery. ❑ Ask if there was similar complaints during previous pregnancy? ❑ Was there any complications throughout the pregnancy or during delivery such as shoulder dystocia, postpartum haemorrhage ? | |||||||||||||||||||||||||||||||||||||||||||||||
Ask the following questions about menstrual history : ❑ Age of menarche ❑ Last menstrual period ❑ Is the menstrual flow normal? How many pads she has to use in a day? ❑ Is there any foul smell or colour change? ❑ How many days does the menstruation stay? ❑ Contraceptive history for example oral contraceptives, intrauterine device | |||||||||||||||||||||||||||||||||||||||||||||||
See if following factors are present: ❑ History of hypertension | |||||||||||||||||||||||||||||||||||||||||||||||
Do laboratory tests[1]: ❑ Dipstick testing ❑ If dipstick test is positive (one protein or more), the use of either spot urine albumin to creatinine (A:Cr) or protein to creatinine (P:Cr) ratios are recommended to quantify proteinuria.[2] ❑ Haemoglobin ❑ Platelet count ❑ Serum creatinine ❑ Liver enzymes ❑ Serum uric acid ❑ Use of PlGF or sFlt-1:PlGF ratio to help rule out preeclampsia in women between 20 and 34 + 6 weeks’ gestation in whom preeclampsia is suspected.[13] ❑ Ultrasound assessment of fetal growth and umbilical artery doppler velocimetry or cerebroplacental ratio measurements to assess blood flow redistribution in placental insufficiency. | |||||||||||||||||||||||||||||||||||||||||||||||
PRE-ECLAMPSIA:Preeclampsia is defined as Gestational Hypertension associated with new-onset maternal or uteroplacental dysfunction at or after 20 Weeks’ Gestation ❑ Gestational Hypertension : blood pressure higher than 140/90 measured on two separate occasions, more than 6 hours apart.[14] | |||||||||||||||||||||||||||||||||||||||||||||||
Treatment
Shown below is an algorithm summarizing the treatment of mild hypertension and preeclampsia.
Woman with mild hypertension and preeclampsia | |||||||||||||||||||||||||||||||||||||||||||||
Evaluate maternal and fetal condition | |||||||||||||||||||||||||||||||||||||||||||||
❑ ≥ 37 weeks of gestation, Bishop score ≥ 6, non-complaint patient ❑ ≥34 weeks gestation, Labor or rupture of membranes, Abnormal fetal testing, Intrauterine growth restriction | Yes | Delivery | |||||||||||||||||||||||||||||||||||||||||||
No | |||||||||||||||||||||||||||||||||||||||||||||
↑ | |||||||||||||||||||||||||||||||||||||||||||||
<37 weeks | 37-39 weeks | → | Prostaglandin | ||||||||||||||||||||||||||||||||||||||||||
❑ Fetal and maternal monitoring on a regular basis ❑ Inpatient and outpatient management | ↑ | ||||||||||||||||||||||||||||||||||||||||||||
→ | |||||||||||||||||||||||||||||||||||||||||||||
Shown below is an algorithm summarizing the treatment of severe preeclampsia.
Woman with severe pre eclampsia | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
❑ Evaluate maternal and fetal condition for 24 hours. ❑ Administer Magnesium sulphate X 24 hours. ❑ Anti-hypertensives if systolic blood pressure ≥ 160mm Hg, diastolic blood pressure ≥110 mmHg and meant aretrial blood pressure ≥125 mmHg | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Check if following are present: --- ❑ Maternal distress❑ Non-reassuring fetal status. ❑ Labor or rupture of membranes. ❑ >34 weeks of gestation. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Yes | No | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
↑ | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Severe intrauterine growth restriction | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Yes | No | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
← | Steroids | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
↑ | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
← | 33-34 weeks of gestation | 23-32 weeks of gestation | <23 weeks of gestation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
❑ Anti-hypertensives if required. ❑ Daily maternal and fetal evaluation. ❑ Delivery at 34 weeks. | termination of pregnancy | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Drugs for urgent controlling of hypertension in preeclampsia[18] | Dose | Specific considration | Onset of action |
---|---|---|---|
Labetalol | 10–20 mg IV<br>
then 20–80 mg every 10–30 minutes upto a maximum dosage of 300 mg;<br> or <br> infusion 1–2 mg/min IV |
Contraindications: | 1-2 minutes |
Hydralazine | 5 mg IV or IM, then 5–10 mg IV every 20–40 minutes upto a maximum dosage of 200 mg or keeping infusion of 0.5–10 mg/hr | Side effects in higher dosage:
|
10-20 minutes |
Nifedipine | 10–20 mg orally, repeat in 20 minutes if needed; then 10–20 mg every 2–6 hours, maximum daily dose is 180 mg | Side effect:
|
5-10 minutes |
Do's
- Patient should start low-dose aspirin if she has two or more of the moderate-risk factors
Don'ts
- The content in this section is in bullet points.
References
- ↑ 1.0 1.1 Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S, Hall DR, Warren CE, Adoyi G, Ishaku S (July 2018). "Hypertensive Disorders of Pregnancy: ISSHP Classification, Diagnosis, and Management Recommendations for International Practice". Hypertension. 72 (1): 24–43. doi:10.1161/HYPERTENSIONAHA.117.10803. PMID 29899139.
- ↑ 2.0 2.1 "Overview | Hypertension in pregnancy: diagnosis and management | Guidance | NICE".
- ↑ 3.0 3.1 North RA, McCowan LM, Dekker GA, Poston L, Chan EH, Stewart AW, Black MA, Taylor RS, Walker JJ, Baker PN, Kenny LC (April 2011). "Clinical risk prediction for pre-eclampsia in nulliparous women: development of model in international prospective cohort". BMJ. 342: d1875. doi:10.1136/bmj.d1875. PMC 3072235. PMID 21474517.
- ↑ Bahri Khomami M, Joham AE, Boyle JA, Piltonen T, Silagy M, Arora C, Misso ML, Teede HJ, Moran LJ (May 2019). "Increased maternal pregnancy complications in polycystic ovary syndrome appear to be independent of obesity-A systematic review, meta-analysis, and meta-regression". Obes Rev. 20 (5): 659–674. doi:10.1111/obr.12829. PMID 30674081.
- ↑ Qin JZ, Pang LH, Li MJ, Fan XJ, Huang RD, Chen HY (June 2013). "Obstetric complications in women with polycystic ovary syndrome: a systematic review and meta-analysis". Reprod Biol Endocrinol. 11: 56. doi:10.1186/1477-7827-11-56. PMC 3737012. PMID 23800002.
- ↑ Pamidi S, Pinto LM, Marc I, Benedetti A, Schwartzman K, Kimoff RJ (January 2014). "Maternal sleep-disordered breathing and adverse pregnancy outcomes: a systematic review and metaanalysis". Am J Obstet Gynecol. 210 (1): 52.e1–52.e14. doi:10.1016/j.ajog.2013.07.033. PMID 23911687.
- ↑ Rustveld LO, Kelsey SF, Sharma R (March 2008). "Association between maternal infections and preeclampsia: a systematic review of epidemiologic studies". Matern Child Health J. 12 (2): 223–42. doi:10.1007/s10995-007-0224-1. PMID 17577649.
- ↑ Bellos I, Daskalakis G, Pergialiotis V (February 2018). "Helicobacter pylori infection increases the risk of developing preeclampsia: A meta-analysis of observational studies". Int J Clin Pract. 72 (2). doi:10.1111/ijcp.13064. PMID 29388723.
- ↑ Blázquez A, García D, Rodríguez A, Vassena R, Figueras F, Vernaeve V (July 2016). "Is oocyte donation a risk factor for preeclampsia? A systematic review and meta-analysis". J Assist Reprod Genet. 33 (7): 855–63. doi:10.1007/s10815-016-0701-9. PMC 4930777. PMID 27007875.
- ↑ Masoudian P, Nasr A, de Nanassy J, Fung-Kee-Fung K, Bainbridge SA, El Demellawy D (March 2016). "Oocyte donation pregnancies and the risk of preeclampsia or gestational hypertension: a systematic review and metaanalysis". Am J Obstet Gynecol. 214 (3): 328–39. doi:10.1016/j.ajog.2015.11.020. PMID 26627731.
- ↑ Lye, P.; Bloise, E.; Dunk, C.; Javam, M.; Gibb, W.; Lye, S.J.; Matthews, S.G. (2013). "Effect of oxygen on multidrug resistance in the first trimester human placenta". Placenta. 34 (9): 817–823. doi:10.1016/j.placenta.2013.05.010. ISSN 0143-4004.
- ↑ Mayrink, J.; Costa, M. L.; Cecatti, J. G. (2018). "Preeclampsia in 2018: Revisiting Concepts, Physiopathology, and Prediction". The Scientific World Journal. 2018: 1–9. doi:10.1155/2018/6268276. ISSN 2356-6140.
- ↑ Zeisler H, Llurba E, Chantraine F, Vatish M, Staff AC, Sennström M, Olovsson M, Brennecke SP, Stepan H, Allegranza D, Dilba P, Schoedl M, Hund M, Verlohren S (January 2016). "Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia". N Engl J Med. 374 (1): 13–22. doi:10.1056/NEJMoa1414838. PMID 26735990.
- ↑ Lo JO, Mission JF, Caughey AB (April 2013). "Hypertensive disease of pregnancy and maternal mortality". Curr Opin Obstet Gynecol. 25 (2): 124–32. doi:10.1097/GCO.0b013e32835e0ef5. PMID 23403779.
- ↑ Fox R, Kitt J, Leeson P, Aye C, Lewandowski AJ (October 2019). "Preeclampsia: Risk Factors, Diagnosis, Management, and the Cardiovascular Impact on the Offspring". J Clin Med. 8 (10). doi:10.3390/jcm8101625. PMC 6832549 Check
|pmc=
value (help). PMID 31590294. Vancouver style error: initials (help) - ↑ Price CP, Newall RG, Boyd JC (September 2005). "Use of protein:creatinine ratio measurements on random urine samples for prediction of significant proteinuria: a systematic review". Clin Chem. 51 (9): 1577–86. doi:10.1373/clinchem.2005.049742. PMID 16020501.
- ↑ Kucukgoz Gulec U, Sucu M, Ozgunen FT, Buyukkurt S, Guzel AB, Paydas S (October 2017). "Spot Urine Protein-to-Creatinine Ratio to Predict the Magnitude of 24-Hour Total Proteinuria in Preeclampsia of Varying Severity". J Obstet Gynaecol Can. 39 (10): 854–860. doi:10.1016/j.jogc.2017.04.035. PMID 28647444.
- ↑ "Gestational Hypertension and Preeclampsia". Obstetrics & Gynecology. 135 (6): e237–e260. 2020. doi:10.1097/AOG.0000000000003891. ISSN 0029-7844.